HemoTimes The Roche Acquisition of Spark Hits a Delay Due to Regulatory Review Process
Swiss pharma giant Roche said it has pushed back its planned timeline for the acquisition of Spark Therapeutics in order to provide the U.S. government additional time to complete its review of the proposed $4.8 billion transaction.